natgillin/translations-raw huggingface dataset:
I kliniske studier af reumatoid arthritis var hyppigheden af alvorlige infektioner højere hos infliximab-plus methotrexatbehandlede patienter på 65 år og derover (11,3 %) sammenlignet med patienter under 65 år (4,6 %). 
In rheumatoid arthritis clinical studies, the incidence of serious infections was greater in infliximab plus methotrexate-treated patients 65 years and older (11.3%) than in those under 65 years of age (4.6%).
PATIENT-INFORMATIONSKORT 
PATIENT REMINDER CARD
• Flere børn end voksne, der får infliximab, fik infektioner. 
• More children taking infliximab developed infections as compared to adults.
Effekten af infliximab blev vurderet i to multicenter, randomiserede, dobbeltblinde, basale kliniske studier. 
The efficacy of infliximab was assessed in two multicentre, randomised, double-blind, pivotal clinical studies.
Patienterne fik 3 eller 6 mg/kg infliximab som et 3 dose induktionsregi (hhv. uge 0, 2, 6 eller uge 14, 16, 20) fulgt af vedligeholdelsesbehandling hver 8. uge i kombination med methotrexat. 
Patients received 3 or 6 mg/kg infliximab as a 3dose induction regimen (weeks 0, 2, 6 or weeks 14, 16, 20 respectively) followed by maintenance therapy every 8 weeks, in combination with methotrexate.
Fortynd den samlede dosis (volumen) af det rekonstituerede Zessly-koncentrat til 250 ml med natriumchlorid 9 mg/ml (0,9 %) infusionsvæske. 
Dilute the total volume of the reconstituted Zessly solution dose to 250 ml with sodium chloride 9 mg/ml (0.9%) solution for infusion.
De bivirkninger, som børn i behandling med infliximab mod Crohns sygdom fik, var forskellige fra de bivirkninger, som voksne i behandling med infliximab mod Crohns sygdom fik. 
Children who took infliximab for Crohn's disease showed some differences in side effects compared with adults who took infliximab for Crohn's disease.
I et toksicitetsstudie vedrørende udvikling udført på mus ved brug af et analogt antistof, der selektivt hæmmer den funktionelle aktivitet af muse TNFα, var der ingen tegn på maternel toksicitet, embryotoksicitet eller teratogenicitet. 
In a developmental toxicity study conducted in mice using an analogous antibody that selectively inhibits the functional activity of mouse TNFα, there was no indication of maternal toxicity, embryotoxicity or teratogenicity.
Under overvågning efter markedsføring er der rapporteret tilfælde af gulsot og hepatitis, nogle med tegn på autoimmun hepatitis, hos patienter, der fik infliximab (se pkt. 
In post-marketing surveillance, cases of jaundice and hepatitis, some with features of autoimmune hepatitis, have been reported in patients receiving infliximab (see section
Klinisk responsa Klinisk remission Steroidfri remission 
Clinical Responsea Clinical Remission
• Øvrige indholdsstoffer: dinatriumsuccinathexahydrat, ravsyre, saccharose, polysorbat 80. 
• The other ingredients are disodium succinate hexahydrate, succinic acid, sucrose, polysorbate 80.
PGA helt væk (0) eller minimale (1) PGA helt væk (0), minimale (1) eller lette (2) 
PGA of cleared (0) or minimal (1) PGA of cleared (0), minimal (1), or mild (2)
Seponering af Zesslybehandling bør overvejes hos patienter, hvor signifikante blodanormaliteter er bekræftet. 
Discontinuation of Zessly therapy should be considered in patients with confirmed significant haematologic abnormalities.
En risiko for udvikling af hepatosplenisk T-celle-lymfom hos patienter, der bliver behandlet med infliximab, kan ikke udelukkes (se pkt. 
A risk for the development for hepatosplenic T-cell lymphoma in patients treated with infliximab cannot be excluded (see section 4.8).
Følgende bivirkninger forekom hyppigere hos børn: nedsat antal røde blodlegemer (anæmi), blod i afføringen, nedsat samlet indhold af hvide blodlegemer (leukopeni), anfaldsvis ansigtsrødme, virusinfektioner, lavt indhold af hvide blodlegemer, der bekæmper infektion (neutropeni), knoglebrud, bakterieinfektion og allergiske reaktioner i luftvejene. 
The side effects that happened more in children were: low red blood cells (anaemia), blood in stool, low overall levels of white blood cells (leukopenia), redness or blushing (flushing), viral infections, low levels of white blood cells that fight infection (neutropenia), bone fracture, bacterial infection and allergic reactions of the breathing tract.
I det andet kliniske studie (studie 9) blev 279 patienter randomiseret til behandling med enten placebo (gruppe 1, n = 78) eller 5 mg/kg infliximab (gruppe 2, n = 201) i uge 0, 2 og 6 og derefter hver 6. uge indtil uge 24. 
In the second clinical study, (study 9), 279 patients were randomised to receive either placebo (Group 1, n = 78) or 5 mg/kg infliximab (Group 2, n = 201) at 0, 2, and 6 weeks and every 6 weeks to week 24.
Hvis tegn og symptomer på sygdom vender tilbage, kan Zessly indgives på ny inden for 16 uger efter den seneste infusion. 
Re-administration for Crohn's disease and rheumatoid arthritis If the signs and symptoms of disease recur, Zessly can be re-administered within 16 weeks following the last infusion.
Opbevares ved 2 °C - 8 °C. 
Store at 2°C - 8°C.
Kan opbevares ved almindelig temperatur (op til 30 °C) i en enkelt periode på op til 6 måneder, men den oprindelige udløbsdato må ikke overskrides. 
Can be stored at temperatures up to 30°C for a single period up to 6 months, but not exceeding the original expiry date.
Effekten af infliximab blev vurderet i to multicenter, randomiserede, dobbeltblinde studier: studie 12 og 13. 
The efficacy of infliximab was assessed in two multicenter, randomised, double-blind studies 12 and 13.
Den samlede forekomst af infektioner i studiet med colitis ulcerosa hos børn var 13/22 (59 %) i 8-ugers vedligeholdelsesbehandlingsgruppen og 14/23 (60,9 %) i 12-ugers vedligeholdelsesbehandlingsgruppen. 
The overall incidence of infections in the paediatric ulcerative colitis trial was 13/22 (59%) in the every 8 week maintenance treatment group and 14/23 (60.9%) in the every 12 week maintenance treatment group.
Sikkerhed og effekt ved infliximab blev vurderet i to (studie 6 og 7) randomiserede, dobbeltblinde, placebokontrollerede kliniske studier hos voksne patienter med moderat til svær, aktiv colitis ulcerosa (Mayo score 6 til 12; Endoskopi subscore ≥ 2) med et utilstrækkeligt respons på konventionel behandling [orale kortikosteroider, aminosalicylater og/eller immunmodulatorer (6-MP, AZA)]. 
The safety and efficacy of infliximab were assessed in two (studies 6 and 7) randomised, doubleblind, placebo-controlled clinical studies in adult patients with moderately to severely active ulcerative colitis (Mayo score 6 to 12; Endoscopy subscore ≥ 2) with an inadequate response to conventional therapies [oral corticosteroids, aminosalicylates and/or immunomodulators (6-MP, AZA)].
• Tegn på leverproblemer (inklusive hepatitis B-infektion, hvis du tidligere har haft hepatitis B) såsom gulfarvning af hud eller øjne, mørkebrun urin, smerter eller hævelser i øvre højre side af maven, ledsmerter, hududslæt eller feber. 
• Signs of a liver problem (including hepatitis B infection when you have had hepatitis B in the past) such as yellowing of the skin or eyes, dark-brown coloured urine pain or swelling in the upper right side of the stomach area, joint pain, skin rashes, or fever.
Hvis opløsningen er klargjort under aseptiske betingelser, kan den dog opbevares i køleskab ved 2°C - 8°C i 24 timer. 
However, if the solution is prepared in germ-free conditions, it can be stored in a refrigerator at 2°C - 8°C for 24 hours.
Der var færre forsøgspersoner, som fik foretaget kolektomi i 5 mg/kg infliximab-gruppen (28/242 eller 11,6 % [N.S.] og 10 mg/kg infliximab-gruppen (18/242 eller 7.4 % [p = 0,011]) end i placebogruppen (36/244;14,8 %). 
Fewer subjects underwent colectomy in the 5 mg/kg infliximab group (28/242 or 11.6% [N.S.]) and the 10 mg/kg infliximab group (18/242 or 7.4% [p = 0.011]) than in the placebo group
• Behandle aktiv Crohns sygdom 
• treat active Crohn's disease
• Tegn på en allergisk reaktion såsom hævelse af ansigt, læber, mund eller svælg, som kan forårsage besvær med at synke eller trække vejret, kløende udslæt, hævelse af hænder, fødder eller ankler. 
• Signs of an allergic reaction such as swelling of your face, lips, mouth or throat, which may cause difficulty in swallowing or breathing, skin rash, hives, swelling of the hands, feet or ankles.
Infliximabs sikkerhed og virkning hos børn og unge under 18 år for indikationerne juvenil idiopatisk arthritis, psoriasis arthritis og ankyloserende spondylitis er ikke klarlagt. 
The safety and efficacy of infliximab in children and adolescents younger than 18 years for the indications of juvenile idiopathic arthritis, psoriatic arthritis and ankylosing spondylitis have not been established.
Patienter med ACR20 respons /Patienter evalueret ( %) 
Patients with ACR20 response/
Alle infliximabb 
All infliximabb
Debuterende eller forværring af allerede eksisterende psoriasis, inklusive pustuløs psoriasis (primært palmoplantaris), urticaria, udslæt, pruritus, øget svedtendens, tør hud, svampedermatitis, eksem, alopeci. 
New onset or worsening psoriasis including pustular psoriasis (primarily palm & soles), urticaria, rash, pruritus, hyperhidrosis, dry skin, fungal dermatitis, eczema, alopecia.
Infliximabs sikkerhed og virkning blev vurderet i et multicenter, randomiseret, open-label, parallelgruppe klinisk studie 15 hos 60 pædiatriske patienter i alderen 6 til 17 år (medianalder 14,5 år) med moderat til svær aktiv colitis ulcerosa (Mayo-score på 6-12; endoskopisk subscore ≥ 2) med utilstrækkelig respons på konventionel behandling. 
The safety and efficacy of infliximab were assessed in a multicenter, randomised, open-label, parallel-group clinical study 15 in 60 paediatric patients aged 6 through 17 years (median age 14.5 years) with moderately to severely active ulcerative colitis (Mayo score of 6 to 12; endoscopic subscore ≥ 2) with an inadequate response to conventional therapies.
En større andel patienter i den kombinerede infliximab-behandlingsgruppe var i stand til at afbryde kortikosteroider og stadig blive i klinisk remission sammenlignet med placebobehandlingsgruppen i både uge 30 (22,3 % mod 7,2 %, p < 0,001, samlede studie 6 og studie 7 data) og uge 54 (21,0 % mod 8,9 %, p = 0,022, studie 6 data). 
A greater proportion of patients in the combined infliximab treatment group were able to discontinue corticosteroids while remaining in clinical remission compared to the placebo treatment group at both week 30 (22.3% vs. 7.2%, p < 0.001, pooled study 6 & study 7 data) and week 54 (21.0% vs. 8.9%, p = 0.022, study 6 data).
Patienterne fik 5 mg/kg infliximab eller placebo infusioner i uge 0, 2 og 6 efterfulgt af vedligeholdelsesbehandling hver 8. uge indtil uge 22 i placebogruppen og indtil uge 46 i infliximab-gruppen. 
Patients received 5 mg/kg infliximab- or placebo-infusions at weeks 0, 2, and 6 followed by maintenance therapy every 8 weeks through week 22 in the placebo group and through week 46 in the infliximab group.
3. dosis 
3rd dose
Zessly 100 mg pulver til koncentrat infliximab 
Zessly 100 mg powder for concentrate infliximab
5.1): anæmi (10,7 %), blod i afføringen (9,7 %), leukopeni (8,7 %), rødmen (8,7 %), viral infektion (7,8 %), neutropeni (6,8 %), bakteriel infektion (5,8 %) og allergisk reaktion i luftvejene (5,8 %). 
The following adverse reactions were reported more commonly in paediatric Crohn's disease patients (see section 5.1) than in adult Crohn's disease patients: anaemia (10.7%), blood in stool (9.7%), leukopenia (8.7%), flushing (8.7%), viral infection (7.8%), neutropenia (6.8%), bacterial infection (5.8%), and respiratory tract allergic reaction (5.8%).
• Fornyet indgift: Doser på 5 mg/kg, hvis sygdomstegn og symptomer på sygdommen kommer igen (se ‘Fornyet indgift' nedenfor samt pkt. 
• Re-administration: Infusion of 5 mg/kg if signs and symptoms of the disease recur (see ‘Re administration' below and section 4.4).
Otteogtres procent (21/31) af patienter behandlet med infliximab, der fik et 5 mg/kg doseringsregimen, opnåede en klinisk effekt mod 26 % (8/31) af placebobehandlede patienter (p = 0,002). 
Sixty eight percent (21/31) of infliximab-treated patients receiving a 5 mg/kg dose regimen achieved a clinical response vs. 26% (8/31) placebo-treated patients (p = 0.002).
Zessly er indiceret til behandling af moderat til svær plaque psoriasis hos voksne patienter, som ikke responderede på, eller som har en kontraindikation for eller som ikke tåler anden systemisk behandling inklusive ciclosporin, methotrexat eller PUVA (se pkt. 
Zessly is indicated for treatment of moderate to severe plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA (see section 5.1).
Samtidig anvendelse af TNF-alfahæmmere og abatacept har i kliniske studier været forbundet med en øget risiko for infektioner, inklusive alvorlige infektioner, uden en øget klinisk fordel, sammenlignet med TNF-hæmmere alene. 
In clinical studies concurrent administration of TNF-antagonists and abatacept has been associated with an increased risk of infections including serious infections compared to TNF-antagonists alone, without increased clinical benefit.
a p < 0,001, for hver infliximab-behandlingsgruppe versus kontrol. 
a p < 0.001, for each infliximab treatment group vs. control.
• Andre hudproblemer såsom erythema multiforme, lichenoide reaktioner (kløende, rødligt-lilla hududslæt og/eller trådlignende gråhvide linjer på slimhinderne), blærer og afskalning af huden, 
• Other skin problems such as erythema multiforme, lichenoid reactions (itchy reddish-purple skin rash and/or threadlike white-grey lines on mucous membranes), blisters and peeling skin, or boils (furunculosis)
Se afsnittet om Graviditet, amning og frugtbarhed for yderligere information. 
For more information see section on Pregnancy and breastfeeding.
Der er rapporteret om enkelte tilfælde af aktiv tuberkulose under og efter behandling for latent tuberkulose hos patienter i behandling med infliximab. 
Some cases of active tuberculosis have been reported in patients treated with infliximab during and after treatment for latent tuberculosis.
Fortæl straks din læge, hvis du får nye eller forværrede tegn på hjertesvigt under behandlingen med Zessly. 
Tell your doctor straight away if you get new or worsening signs of heart failure during treatment with Zessly.
Brug af anden medicin sammen med Zessly 
Other medicines and Zessly
I begge studier var patienterne randomiseret til at få enten placebo, 5 mg/kg infliximab eller 10 mg/kg infliximab i uge 0, 2, 6, 14 og 22, og i studie 6 i uge 30, 38 og 46. 
In both studies, patients were randomised to receive either placebo, 5 mg/kg infliximab, or 10 mg/kg infliximab at weeks 0, 2, 6, 14, and 22, and in study 6 at weeks 30, 38, and 46.
I et toksicitetsstudie vedrørende udvikling udført på mus med et analogt antistof, som selektivt hæmmer den funktionelle aktivitet af muse-TNFα, var der ingen tegn på maternel toksicitet, embryotoksicitet eller teratogenicitet (se pkt. 
In a developmental toxicity study conducted in mice using an analogous antibody that selectively inhibits the functional activity of mouse TNFα, there was no indication of maternal toxicity, embryotoxicity or teratogenicity (see section 5.3).
Efter markedsføring er der rapporteret tilfælde af forværret hjerteinsufficiens hos infliximab patienter, med eller uden identificerbare predisponerende faktorer. 
There have been post-marketing reports of worsening heart failure, with and without identifiable precipitating factors, in patients taking infliximab.
(p < 0,001)* * P-værdier repræsenterer hver infliximab-behandlingsgruppe vs. AZA monoterapi. 
* P-values represent each infliximab treatment group vs. AZA monotherapy.
Sikkerhed og effekt ved fornyet indgift, udover hver 6. til 8. uge, er ikke vist (se pkt. 
The safety and efficacy of re-administration, other than every 6 to 8 weeks, has not been established (see sections 4.4 and 4.8).
I det første studie (studie 8), som havde en dobbelblind fase på 3 måneder, modtog 70 patienter enten 5 mg/kg infliximab eller placebo i uge 0, 2, 6 (35 patienter i hver gruppe). 
In the first study, (study 8), which had a 3 month double-blind phase, 70 patients received either 5 mg/kg infliximab or placebo at weeks 0, 2, 6 (35 patients in each group).
I fase III kliniske studier oplevede 18 % af de infliximab-behandlede patienter en infusionsrelateret reaktion sammenlignet med 5 % af de placebobehandlede patienter. 
In Phase III clinical studies, 18% of infliximabtreated patients compared with 5% of placebo-treated patients experienced an infusion-related reaction.
Antal patienter3 Medianopfølgning (uger)4 
Median follow-up (wks)4
Når rekonstitution og fortynding er udført under aseptiske forhold, kan Zessly infusionsvæske anvendes inden for 24 timer, hvis den opbevares ved 2°C - 8°C. 
When reconstitution and dilution are performed under aseptic conditions, Zessly infusion solution can be used within 24 hours if stored at 2°C - 8°C.
I alt 306 patienter fik 3 doser infliximab på 5 mg/kg i ugerne 0, 2 og 6. 
A total of 306 patients received 3 doses of infliximab 5 mg/kg at week 0, 2, and 6.
Infliximabs sikkerhed og virkning hos børn under 6 år med Crohns sygdom er ikke klarlagt. 
The safety and efficacy of infliximab have not been studied in children with Crohn's disease below the age of 6 years.
4.4 og 4.8 for mere information omkring sikkerhed ved brug af infliximab hos ældre patienter. 
For more information about the safety of infliximab in elderly patients see sections 4.4 and 4.8.
Det anbefales, at pædiatriske patienter bliver vaccineret i overensstemmelse med gældende vaccinationsvejledninger, før Zesslybehandling påbegyndes, hvis dette er muligt. 
It is recommended that paediatric patients, if possible, be brought up to date with all vaccinations in agreement with current vaccination guidelines prior to initiating Zessly therapy.
Ankyloserende spondylitis (Bekhterevs sygdom) 
Ankylosing spondylitis (Bechterew's disease)
Patienterne modtog tre doser af enten placebo eller infliximab i uge 0, 2 og 6. 
Patients received three doses of either placebo or infliximab at weeks 0, 2, and 6.
Meget almindelig: (kan forekomme hos flere end 1 ud af 10 personer) 
Very common (may affect more than 1 in 10 people)
Samtidig administration af levende vacciner og Zessly frarådes. 
The concurrent administration of live vaccines with Zessly is not recommended.
infliximab + MTX Placebo + MTX 3 mg/kg 6 mg/kg Kombineret 
Placebo + MTX 3 mg/kg
Neutropeni, leukopeni, anæmi, lymfadenopati. 
Neutropenia, leukopenia, anaemia, lymphadenopathy.
Effekten af en éndosis behandling med infliximab blev vurderet hos 108 patienter med aktiv Crohns sygdom (Crohn's Disease Activity Index (CDAI) ≥ 220 ≤ 400) i et randomiseret, dobbeltblindet, placebokontrolleret, dosis-virknings studie. 
Crohn's disease (Crohn's Disease Activity Index (CDAI) ≥ 220 ≤ 400) in a randomised, double blinded, placebo-controlled, dose-response study.
Tegn inkludererfeber, hoste, influenzalignende symptomer, utilpashed, rød eller ophedet hud, sår eller problemer med tænderne. 
Signs include fever, cough, flu-like signs, feeling unwell, red or hot skin, wounds or dental problems.
Infliximab med eller uden AZA blev vurderet i et randomiseret, dobbeltblind studie med aktiv komparator hos 508 voksne patienter med moderat til svær Crohns sygdom (CDAI ≥ 220 ≤ 450). 
Infliximab with or without AZA was assessed in a randomised, double-blind, active comparator study of 508 adult patients with moderate to severe Crohn's disease (CDAI ≥ 220 ≤ 450) who were naive to biologics and immunosuppressants and had a median disease duration of 2.3 years.
I et populationsbaseret, retrospektivt kohortestudie sås en øget incidens af livmoderhalskræft hos kvinder med reumatoid arthritis, som var blevet behandlet med infliximab, sammenlignet med patienter, der var naive i forhold til biologiske lægemidler, eller befolkningen generelt, inklusive kvinder over 60 år (se pkt. 
A population-based retrospective cohort study found an increased incidence of cervical cancer in women with rheumatoid arthritis treated with infliximab compared to biologics-naïve patients or the general population, including those over 60 years of age (see section 4.4).
• Tegn på en sygdom i immunsystemet såsom ledsmerter, udslæt på kinder eller arme, som er følsomme over for solen (lupus) eller hoste, åndenød, feber eller hududslæt (sarkoidose). 
• Signs of an immune system disorder such as joint pain or a rash on cheeks or arms that is sensitive to the sun (lupus) or cough, shortness of breath, fever or skin rash (sarcoidosis)..
Pædiatriske patienter, der får infliximab, kan få vaccinationer samtidigt, med undtagelse af levende vacciner (se pkt. 
Paediatric patients on infliximab may receive concurrent vaccinations, except for live vaccines (see sections 4.5 and
Analysen var baseret på patienter med neglepsoriasis ved baseline (81,8 % af patienterne). 
b n = 292. c Analysis was based on subjects with nail psoriasis at baseline (81.8% of subjects).
Hos patienter med positiv test for HBV-infektion, anbefales det at rådføre sig med en læge med erfaring i behandling af hepatitis B. Bærere af HBV, hvor behandling med Zessly er nødvendig, skal følges nøje under behandlingen og i adskillige måneder efter afslutning af behandlingen for at registere tegn og symptomer på aktiv HBV-infektion. 
Carriers of HBV who require treatment with Zessly should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy.
Vertigo, svimmelhed, hypæstesi, paræstesi. 
Vertigo, dizziness, hypoesthesia, paraesthesia.
• Tegn på hjerteproblemer såsom ubehag i brystkassen eller brystsmerter, armsmerter, mavesmerter, åndenød, angst, ørhed, svimmelhed, besvimelse, svedtendens, kvalme (utilpashed), opkastning, skælven eller banken i brystet, hurtigt eller langsomt hjerteslag og hævede fødder. 
• Signs of a heart problem such as chest discomfort or pain, arm pain, stomach pain, shortness of breath, anxiety, light-headedness, dizziness, fainting, sweating, nausea (feeling seek), vomiting, fluttering or pounding in your chest, a fast or a slow heartbeat, and swelling of your feet.
Sikkerhed og effekt ved fornyet indgift, udover hver 8. uge, er ikke vist (se pkt. 
The safety and efficacy of re-administration, other than every 8 weeks, has not been established (see sections 4.4 and 4.8).
Sjælden: (kan forekomme hos op til 1 ud af 1.000 personer) 
Rare (may affect up to 1 in 1,000 people)
Zessly er indiceret til behandling af moderat til svær, aktiv colitis ulcerosa hos voksne patienter, som har haft utilstrækkelig respons af konventionel behandling inklusive kortikosteroider og 6-mercaptopurin (6-MP) eller azathioprin (AZA), eller som er intolerante over for eller har kliniske kontraindikationer for sådanne behandlinger. 
Zessly is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.
Hjælpestoffer: Dinatriumsuccinathexahydrat, ravsyre, saccharose, polysorbat 80. 
Excipients: Disodium succinate hexahydrate, succinic acid, sucrose, polysorbate 80.
5 mg/kg 10 mg/kg 
5 mg/kg
Hos 32 evaluérbare patienter blev doseringen ændret (9 personer i 8. ugers gruppen og 23 i 12. ugers gruppen). 
Thirty two (32) evaluable paediatric patients crossed over (9 subjects in the q8 weeks and 23 subjects in the q12 weeks maintenance groups).
Der er set pancytopeni, leukopeni, neutropeni og trombocytopeni hos patienter, der fik TNF-hæmmere, herunder infliximab. 
There have been reports of pancytopenia, leukopenia, neutropenia, and thrombocytopenia in patients receiving TNF-blockers, including infliximab.